Biological activity of recombinant human growth factors released from biocompatible bone implants
✍ Scribed by Joerg Ziegler; Dominique Anger; Frank Krummenauer; Dieter Breitig; Stefan Fickert; Klaus-Peter Guenther
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 188 KB
- Volume
- 86A
- Category
- Article
- ISSN
- 1549-3296
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The present investigation was performed to study the bioactivity of osteoinductive and osteoproliferative growth factors after release from biocompatible bone implants. Three types of porous carriers were used in this study: hydroxyapatite, alpha tricalcium phosphate, and a neutralized glass ceramic. Implants were loaded with recombinant human bone morphogenetic protein 2 (rh‐BMP‐2) and recombinant human basic fibroblast growth factor (rh‐bFGF) in a concentration of 2 μg/150 μL PBS each. The released growth factors were then applicated into SAOS‐2‐cell cultures. After 3, 5, and 7 days cell differentiation was measured by the activity of alkaline phosphatase (ALP), cell proliferation by using a MTT assay as well as a cell counter. Rh‐BMP‐2 released during the first hour from the scaffolds led to a significant increase of the activity of ALP in the incubated SAOS‐2‐cell culture after 3, 5, and 7 days. However, the incubation with rh‐BMP‐2 released after 24 h was not found to increase the expression of ALP. The incubation of cell cultures with rh‐bFGF released during the first hour led to a significant increase of cell number and of extinction in the MTT assay, whereas this increase was not observed after incubation with rh‐bFGF released after 24 h. The in vitro measured biological activity of released growth factors from the surface of synthetic implants is time‐depending. If prolonged osteoinductive and osteoproliferative potency of growth factors is desired, a modified application technique should be chosen to stabilize those proteins. © 2007 Wiley Periodicals, Inc. J Biomed Mater Res, 2008
📜 SIMILAR VOLUMES
## Abstract Previously, we reported that application of 10 μg recombinant human TGF‐β2 (rhTGF‐β2) enhanced peri‐implant bone formation and bone‐implant contact in a rat model. To further investigate the dose effect, the present experiment evaluated doses of rhTGF‐β2 bracketed around 10 μg (5, 10, 2
## Abstract Previously, combinatorial techniques were used to identify peptide sequences exhibiting high, medium, and low affinity for heparin. Bidomain peptides were synthesized containing a transglutaminase sequence for one domain and one of the heparin‐affinity sequences for the other domain. A
Previous studies showed that recombinant human growth of their cytotoxicity. The major fraction of the bioactivity was hormone (hGH) released from hormone-loaded poly(methyl-released from both of the PMMA cements during the first methacrylate) (PMMA) cement stimulated osteoid formation 24 h, but the